Journal
ANTICANCER RESEARCH
Volume 39, Issue 9, Pages 4781-4786Publisher
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.13662
Keywords
Osteosarcoma; sorafenib; everolimus; drug resistance; PDOX; combination therapy; tumor regression
Categories
Ask authors/readers for more resources
Background/Aim: Osteosarcoma is a rare but recalcitrant type of bone cancer. To discover an effective therapy for osteosarcoma, we used a patient-derived orthotopic xenograft (PDOX) mouse model. A PDOX mouse model has been established for all major cancer types. Strong synergistic efficacy of sorafenib (SFN) and everolimus (EVL) has been demonstrated in several cancers. In the present study, we examined the efficacy of a SFN and EVL combination on a doxorubicin (DOX)-resistant osteosarcoma PDOX. Materials and Methods: The osteosarcoma PDOX models were randomly divided into five treatment groups, each containing six mice: Control; DOX; SFN; EVL; and a combination of SFN and EVL. Mice were treated for 14 days. To observe the efficacy of these treatments, tumor size and body weight were measured, and histological sections were analyzed. Results: Tumor growth regression was observed only in the mice treated with the combination of SFN-EVL. Histological analysis revealed necrosis with degenerative changes in tumors treated with a combination of SFN-EVL. Conclusion: A SFN-EVL combination could be a novel effective treatment option for osteosarcoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available